Abstract
Protection of the brain is strengthened by active transport and ABC transporters. P-glycoprotein (P-gp) at the blood-brain barrier (BBB) functions as an active efflux pump by extruding a substrate from the brain, which is important for maintaining loco-regional homeostasis in the brain and protection against toxic compounds. Importantly, dysfunctional BBB P-gp transport is postulated as an important factor contributing to accumulation of aggregated protein in neurodegenerative disorders such as Alzheimers disease (AD) and Parkinsons disease (PD). Furthermore, P-gp is a major factor in mediating resistance to brain entry of numerous exogenous compounds, including toxins that can be involved in PD pathogenesis. This review highlights the role of altered P-gp function in the pathogenesis and progression of neurodegenerative disease. Also the implications of alterations in P-gp function for the treatment of these diseases are discussed.
Keywords: Blood-brain barrier, P-glycoprotein, [11C]-verapamil PET, Parkinson, Alzheimer, Microglia, pesticides, olfactory neurons, progressive supranuclear palsy (PSP), mutation
Current Pharmaceutical Design
Title: Blood-Brain Barrier P-Glycoprotein Function in Neurodegenerative Disease
Volume: 17 Issue: 26
Author(s): A.L. Bartels
Affiliation:
Keywords: Blood-brain barrier, P-glycoprotein, [11C]-verapamil PET, Parkinson, Alzheimer, Microglia, pesticides, olfactory neurons, progressive supranuclear palsy (PSP), mutation
Abstract: Protection of the brain is strengthened by active transport and ABC transporters. P-glycoprotein (P-gp) at the blood-brain barrier (BBB) functions as an active efflux pump by extruding a substrate from the brain, which is important for maintaining loco-regional homeostasis in the brain and protection against toxic compounds. Importantly, dysfunctional BBB P-gp transport is postulated as an important factor contributing to accumulation of aggregated protein in neurodegenerative disorders such as Alzheimers disease (AD) and Parkinsons disease (PD). Furthermore, P-gp is a major factor in mediating resistance to brain entry of numerous exogenous compounds, including toxins that can be involved in PD pathogenesis. This review highlights the role of altered P-gp function in the pathogenesis and progression of neurodegenerative disease. Also the implications of alterations in P-gp function for the treatment of these diseases are discussed.
Export Options
About this article
Cite this article as:
Bartels A.L., Blood-Brain Barrier P-Glycoprotein Function in Neurodegenerative Disease, Current Pharmaceutical Design 2011; 17 (26) . https://dx.doi.org/10.2174/138161211797440122
DOI https://dx.doi.org/10.2174/138161211797440122 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dental Stem Cell Patents
Recent Patents on DNA & Gene Sequences Endogenous Retroelements in Cellular Senescence and Related Pathogenic Processes: Promising Drug Targets in Age-Related Diseases
Current Drug Targets Management of Glia-Mediated Neuroinflammation and Related Patents
Recent Patents on Inflammation & Allergy Drug Discovery Meet Our Editorial Board Member
Current Pharmaceutical Design Limb-girdle Muscular Dystrophy and Therapy: Insights into Cell and Gene-based Approaches
Current Gene Therapy Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?
Current Alzheimer Research The Protective Effects of Crocetin on Aβ<sub>1-42</sub>-Induced Toxicity in Ht22 Cells
CNS & Neurological Disorders - Drug Targets Role of Ligand-Based Drug Design Methodologies toward the Discovery of New Anti- Alzheimer Agents: Futures Perspectives in Fragment-Based Ligand Design
Current Medicinal Chemistry The Effect of Lipoic Acid on Macro and Trace Metal Levels in Living Tissues Exposed to Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry Cerebrospinal Fluid Proteomes: From Neural Development to Neurodegenerative Diseases
Current Proteomics Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson’s Disease and Huntington’s Disease: A Review
Current Neuropharmacology Can Trehalose Prevent Neurodegeneration? Insights from Experimental Studies
Current Drug Targets Investigation of the Metal Bonding Properties of Some ARA-II Compounds Using Spectrofluorimetric Method
Current Drug Therapy Acetylcholinesterase Inhibitor Donepezil Effects on Plasma β-Hydroxybutyrate Levels in the Treatment of Alzheimer’s Disease
Current Alzheimer Research Patent Review
Combinatorial Chemistry & High Throughput Screening Detour Cum Distance Matrix Based Topological Descriptors for QSAR/QSPR Part-II: Application in Drug Discovery Process
Letters in Drug Design & Discovery Regeneration in a Degenerating Brain: Potential of Allopregnanolone as a Neuroregenerative Agent
Current Alzheimer Research Recent Patents on Light Based Therapies: Photodynamic Therapy, Photothermal Therapy and Photoimmunotherapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Histone Deacetylation and Motor Neuron Degeneration
CNS & Neurological Disorders - Drug Targets Copper and Heme-Mediated Abeta Toxicity: Redox Chemistry, Abeta Oxidations and Anti-ROS Compounds
Current Topics in Medicinal Chemistry